Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Journal: Blood advances
Published: July 19, 2023
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 07, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Journal: Communications medicine
Published: February 01, 2023
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Journal: Investigational new drugs
Published: March 04, 2022
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
Journal: Leukemia & lymphoma
Published: August 02, 2021
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Journal: Blood
Published: November 08, 2018
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 31, 2018
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 06, 2017
Last Updated: 09/26/2026